20th May 2020
- 0 comments
MGB Biopharma, the Glasgow-based biopharmaceutical company developing a novel class of anti-infectives, has announced the successful conclusion of its Phase II clinical study into MGB-BP-3, for the treatment of Clostridium difficile Infection (CDI).
...Register / Login now to read full story
In order to read the full story we need you to be registered with us, please click the links below to login or register.
Back to Homepage